# Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19

> **NCT04836260** · PHASE3 · UNKNOWN · sponsor: **University Hospital, Geneva** · enrollment: 100 (estimated)

## Conditions studied

- Covid19
- Immuno-Deficiency
- Old Age; Debility

## Interventions

- **DRUG:** SARS-CoV-2 convalescent plasma

## Key facts

- **NCT ID:** NCT04836260
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-08
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-04-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04836260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04836260, "Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04836260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*